Publications by authors named "I el Amine"
Background: The SARS-CoV-2 is an extremely contagious and acute viral disease mainly affecting humans.
Objective: To estimate seroprevalence of SARS-CoV-2 neutralizing antibodies (NAbs) for illegible armed force individuals living in Rabat, Morocco.
Method: A convenience sample (N = 2662) was conducted from May 2020 to February 2021.
Article Synopsis
- Outcome-wide analysis enhances the ability to detect subtle health signals and identify exposures that could lead to effective preventive measures.* -
- Recent advances in multivariate statistical techniques are underutilized in exposome research; this paper reviews six methods suitable for outcome-wide exposome analysis using R software, addressing common challenges like dependencies, high dimensionality, and missing data.* -
- The highlighted methods fall into four categories, and the study demonstrates their practicality on a real exposome dataset, recommending dimensionality reduction and Bayesian techniques as particularly effective for handling complex data issues.*
Article Synopsis
- Early-life environmental exposures may contribute to chronic diseases, prompting this study to investigate a comprehensive health score for children linked to a variety of prenatal and postnatal factors.
- Analyzed data from 870 children across six European cohorts, assessing 53 prenatal and 105 childhood environmental factors using a health score based on cardiometabolic, respiratory/allergy, and mental health parameters.
- Findings revealed a lower health score related to maternal smoking and certain pollutants, while higher scores linked to exposure to greenspaces, pets, and healthier lifestyles, highlighting complex relationships between environment and children’s health.
Introduction: Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach to manage PNH. Three complement inhibitors are approved by the European Medicines Agency as targeted therapy for PNH: eculizumab and ravulizumab, two humanized monoclonal antibodies targeting the same complement 5 (C5) epitope, approved in 2007 and 2019, respectively, and the more recently approved cyclic peptide, the complement 3 (C3) inhibitor pegcetacoplan. Although national and international PNH treatment guidelines exist, they do not take into consideration the latest clinical trial evidence.
View Article and Find Full Text PDFParoxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegcetacoplan, inhibits C3, upstream of C5, and has the potential to improve control of complement-mediated hemolysis.
View Article and Find Full Text PDF